# Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors

> **NCT00084734** · PHASE1 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 61 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** capecitabine
- **DRUG:** cisplatin
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00084734
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2009-11
- **Final completion:** 2009-12
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00084734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00084734, "Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00084734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*